1. 1. Sudhakar AJJocs, therapy. History of cancer, ancient and modern treatment methods. 2009;1(2):1. 2. Lacey Jr JV, Devesa SS, Brinton LAJE, mutagenesis m. Recent trends in breast cancer incidence and mortality. 2002;39(2‐3):82-8. 3. Tahergorabi Z, Moodi M, Mesbahzadeh BJJoBUoMS. Breast Cancer: A preventable disease. 2014;21(2):126-41. 4. Okamoto H. History of discoveries and pathogenicity of TT viruses. TT Viruses: Springer
2. 2009. p. 1-20. 5. Komijani M, Bouzari M, Etemadifar M, Zarkesh-Esfahani H, Shaykh-Baygloo N, Ghazimorad A, et al. Torque teno mini virus infection and multiple sclerosis. International Journal of Neuroscience. 2011;121(8):437-41. 6. Zhong S, Yeo W, Tang M, Liu C, Lin Xr, Ho WM, et al. Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. 2002;66(3):428-34. 7. Takeuchi O, Akira SJIr. Innate immunity to virus infection. 2009;227(1):75-86. 8. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JFJPotNAoS. A family of human receptors structurally related to Drosophila Toll. 1998;95(2):588-93. 9. Zur Hausen H, De Villiers E-m. Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity. Google Patents
3. 2017. 10. McLaughlin-Drubin ME, Munger KJBeBA-MBoD. Viruses associated with human cancer. 2008;1782(3):127-50. 11. Spandole-Dinu S, Cimponeriu DG, Crăciun A-M, Radu I, Nica S, Toma M, et al. Prevalence of human anelloviruses in Romanian healthy subjects and patients with common pathologies. 2018;18(1):334. 12. de Villiers E-M, Schmidt R, Delius H, zur Hausen HJJomm. Heterogeneity of TT virus related sequences isolated from human tumour biopsy specimens. 2002;80(1):44-50. 13. Tokita H, Murai S, Kamitsukasa H, Yagura M, Harada H, Takahashi M, et al. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus‐related chronic liver disease. 2002;67(4):501-9. 14. Spandole S, Cimponeriu D, Berca LM, Mihăescu GJAov. Human anelloviruses: an update of molecular, epidemiological and clinical aspects. 2015;160(4):893-908. 15. Figueiredo CP, Franz-Vasconcelos HC, Di Giunta G, Mazzuco TL, Caon T, Fernandes AL, et al. Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma. 2007;48(4):731-5. 16. Bando M, Takahashi M, Ohno S, Hosono T, Hironaka M, Okamoto H, et al. Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer. 2008;13(2):263-9. 17. Cimponeriu D, Ion DA, Spandole S, Apostol P, Toma M, Radu I, et al. Potential implication of genetic polymorphisms and Torque teno virus in sporadic breast cancer. 2013;18(1):7889. 18. Zheng H, Ye L, Fang X, Li B, Wang Y, Xiang X, et al. Torque teno virus (SANBAN Isolate) ORF2 protein suppresses NF-κB pathways via interaction with IκB kinases. 2007;81(21):11917-24. 19. Kincaid RP, Burke JM, Cox JC, de Villiers E-M, Sullivan CSJPp. A human torque teno virus encodes a microRNA that inhibits interferon signaling. 2013;9(12):e1003818. 20. Noreen M, Arshad MJIr. Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. 2015;62(2):234-52. 21. Kutikhin AGJHi. Impact of Toll-like receptor 4 polymorphisms on risk of cancer. 2011;72(2):193-206. 22. Kına I, Sultuybek GK, Soydas T, Yenmis G, Biceroglu H, Dirican A, et al. Variations in Toll-like receptor and nuclear factor-kappa B genes and the risk of glioma. 2018:1-6. 23. Wang X-Q, Liu L, Liu Y, Zhang KJGt, biomarkers m. TLR-2 gene polymorphisms and susceptibility to cancer: evidence from meta-analysis. 2013;17(12):864-72. 24. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. 2010;10(1):382. 25. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, et al. The toll‐like receptor 2 (TLR2)‐196 to‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. 2012;130(6):1470-5. 26. Hosseini SV, Mojtahedi Z, Beizavi Z, Khazraei H, Zamani MJAOBS. Relationship between Arg753Gln Toll-like receptor 2 and Asp299Gly Toll-like receptor 4 genetic variations and susceptibility to colorectal cancer in southern Iran. 2018;70(4):775-9. 27. Semlali A, Alnemari R, Almalki E, Alrashed R, Alanazi M. Toll-Like Receptors Gene Polymorphism and Susceptibility to Cancer Development. Genetic Diversity and Disease Susceptibility: IntechOpen
4. 2018. 28. Takahashi K, Hoshino H, Ohta Y, Yoshida N, Mishiro SJHr. Very high prevalence of TT virus (TTV) infection in general population of Japan revealed by a new set of PCR primers. 1998;12(3):233-9. 29. Wujcicka W, Paradowska E, Studzińska M, Wilczyński J, Nowakowska DJVj. Toll-like receptors genes polymorphisms and the occurrence of HCMV infection among pregnant women. 2017;14(1):64.
5. History of Cancer, Ancient and Modern Treatment Methods